S&P Futures
4,401.00-13.25(-0.30%)Dow Futures
34,888.00-146.00(-0.42%)Nasdaq Futures
15,102.00-15.75(-0.10%)Russell 2000 Futures
2,198.60-14.80(-0.67%)Crude Oil
72.06+0.15(+0.21%)Gold
1,796.40-2.80(-0.16%)
Nascent Biotech, Inc. (NBIO)
Chart Events
Performance Outlook
| Previous Close | 0.0951 |
| Open | 0.0965 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0951 - 0.0978 |
| 52 Week Range | 0.0437 - 0.1595 |
| Volume | 5,135 |
| Avg. Volume | 288,926 |
| Market Cap | 9.488M |
| Beta (5Y Monthly) | -2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0760 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration
SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan BioSolutions (together, the "Partners"), are pleased to announce promising new preliminary preclinical results for the COVID-19 vaccine candidate now progressing under joint development by the Partners.
- ACCESSWIRE
Marble Arch Research Publishes Analyst Research Report on Nascent Biotech
VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO a "Speculative Buy" under its tiered rating system
- ACCESSWIRE
Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the beginning of enrollment of the second cohort in dosing patients for its Phase I trial for Brain Cancer.
